Biotech Startups

Botanical Solution Inc (BSI) uses a patented plant tissue culture platform to produce advanced botanical materials from the Chilean tree Quillaja saponaria, offering a sustainable supply of botanical active ingredients. Its products include the biofungicide Quillibrium (sold in Chile as BotriStop) for high-value crops and the vaccine adjuvant QS-21 for pharmaceutical use.

1 investor

Bovotica develops technology that modulates the rumen microbiome of cattle to reduce methane emissions and improve production efficiency for farmers. It targets the cattle industry with a focus on sustainability and climate impact.

1 investor

1 investor

BrainStorm Cell Therapeutics develops NurOwn, an autologous MSC-NTF cellular therapy platform aimed at treating neurodegenerative diseases with limited treatment options. Its cell therapy is investigational and not yet FDA approved.

1 investor

Bramante Bio manufactures AI-driven robotic instruments and reagents for life sciences research and manufacturing. The company designs hardware that integrates with modern software stacks and provides direct engineering support.

1 investor

Brandon BioCatalyst funds biomedical development opportunities associated with its Member Institutes, offering investments ranging from AU$500,000 to AU$30 million across stages from proof-of-concept to late-stage technologies. It operates an investment process through an Investment Review Committee, with due diligence handled by Brandon Capital.

1 investor

BRC Therapeutics develops and manufactures botanically-derived pharmaceutical products, with expertise spanning drug development and manufacturing for pharmaceutical applications.

1 investor

Breakout is a venture capital firm that has invested for over a decade in science-driven technology companies across biotech, tech-bio, deep tech, and hard tech. It partners with founders scaling scientific innovation and connects them to corporates, strategic partners, and next-stage investors.

1 investor

Breakpoint Therapeutics develops cancer treatments based on modulating DNA damage response pathways. It is a biopharmaceutical company focused on oncology therapeutics.

1 investor

Breakthru is a drug development company that applies medicinal chemistry expertise to accelerate the discovery of breakthrough medicines, emphasizing data-driven decision-making about compound viability.

1 investor

1 investor

Brevel develops scalable production solutions for light-responsive biological systems, serving ingredient companies, biotechnology firms, plant cell culture developers, food manufacturers, cosmetics companies, and pharmaceutical innovators.

1 investor

Bridge Farm Nurseries grows houseplants for the wholesale market with a focus on sustainable cultivation practices. The company operates an industry-leading glasshouse facility established over several decades of growth and diversification.

1 investor

Bridgewest Ventures is a venture capital firm focused on deep technology investments in New Zealand, leveraging the infrastructure and expertise of the Bridgewest Group to help founders scale innovative research from lab to global markets. The firm targets specific verticals including AI, life sciences, software, and hardware, providing capital, strategic guidance, and access to international networks and regulatory infrastructure.

1 investor

Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.

1 investor

Brink Biologics provides NK-92 cell lines and assay panels for antibody-dependent cell-mediated cytotoxicity (ADCC) testing in therapeutic antibody development. The company offers proprietary Neukopanel cell lines and related services to pharmaceutical and biotechnology companies developing cancer and immunotherapy treatments.

1 investor

Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.

1 investor

Broadwing Bio develops antibody-based therapies targeting genetically validated ophthalmology conditions, particularly geographic atrophy and glaucoma, to preserve vision and prevent blindness. The company builds on naturally occurring genetic variants to create novel treatments for ocular diseases.

1 investor

Bruker Cellular Analysis develops technologies for live single-cell biology research, combining optofluidics, live single-cell imaging, functional cell biology, and multiomic data to study cellular function and molecular mechanisms. It serves scientists in academia, biotech and pharmaceutical companies, and contract research organizations, supporting work in cell therapy, therapeutic antibody discovery, vaccine development, and cell line development.

1 investor

BSafe Biotech develops a biological crop protection product for agriculture, described as a new mode of action for biological pest and disease control.

1 investor

BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.

1 investor

BÜHLMANN Laboratories is a life science company based in Switzerland.

1 investor

A testing laboratory that conducts electrical product testing and provides reports against documented standards; it also offers consultancy and training services based on its accumulated testing data.

1 investor

Byorna develops a bioproduction platform that uses eukaryotic cell biofactories to manufacture high-quality messenger RNA (mRNA) at lower cost, isolating the mRNA in cellular subcompartments for extraction and GMP-grade production. Its technology targets mRNA-based therapeutics including vaccines for infectious diseases, cancer treatments, and RNA gene therapy for rare diseases.</parameter> <parameter name="founders">[]

1 investor